AmTech Starts Schering Plough (SGP) at Buy
More News related to SGP
- FDA Says It Is Investigating Potential Link Between Vytorin and Risk of Cancer (MRK, SGP)
- Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
- Schering-Plough (SGP) Reports July Vytorin/Zetia Volume
- Gates' The Bill and Melinda Gates Foundation Shows New Positions in Crocs (CROX), Dick's (DKS) and Raised Stakes in McDonald's (MCD), FedEx (FDX) and AIG (AIG)
- Schering-Plough Expands Its Presence in China, Enters Next Stage of Development
More News related to New Coverage
- Raymond James Downgrades 8 Restaurant Stocks Today
- Merrill Lynch Downgrades General Dynamics (GD) to Neutral
- Deutshe Bank Downgrades Cavium Networks (CAVM) to Hold
- Sandler O'Neill Downgrades Boston Private (BPFH) to Sell
- Raymond James Downgrades Hibbet Sports (HIBB) to Market Perform
American Technology Research initiates coverage on Schering Plough (NYSE: SGP) with a Buy rating.
Schering-Plough Corporation discovers, develops, manufactures, and sells pharmaceuticals worldwide.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
